Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C
published in: The lancet. Gastroenterology & hepatology
date of publication: 2017-08-10
language: English
main subject: Hepatitis C virus
Cites articles 11
Date
Title
Article - wd:Q40085046